Cancer Immunology and Immunotherapy de Glenn Dranoff

Cancer Immunology and Immunotherapy: Current Topics in Microbiology and Immunology, cartea 344

Editat de Glenn Dranoff

en Limba Engleză Paperback – 29 mai 2013

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.

Citește tot Restrânge

Toate formatele și edițiile

	Preț	Express
Paperback (1)	1370^.65 lei 6-8 săpt.
Springer Berlin, Heidelberg – 29 mai 2013	1370^.65 lei 6-8 săpt.
Hardback (1)	1375^.06 lei 6-8 săpt.
Springer Berlin, Heidelberg – 15 apr 2011	1375^.06 lei 6-8 săpt.

Din seria Current Topics in Microbiology and Immunology

Preț: 1370^.65 lei

Preț vechi: 1442^.78 lei
-5% Nou

Puncte Express: 2056

:
262^.34€ • 273^.42$ • 218^.39£

Carte tipărită la comandă

Livrare economică 04-18 ianuarie 25

Adaugă în coș

Wish list
Gift list
Am citit!

Adaugă în listă

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783642267888
ISBN-10: 3642267882
Pagini: 320
Ilustrații: XIV, 306 p.
Dimensiuni: 155 x 235 x 17 mm
Greutate: 0.45 kg
Ediția:2011
Editura: Springer Berlin, Heidelberg
Colecția Springer
Seria Current Topics in Microbiology and Immunology

Locul publicării:Berlin, Heidelberg, Germany

Public țintă

Research

Recenzii

From the reviews:
“This book comprises 13 reviews, contributed by members of a cross-section of groups working in the … field of cancer immunology. … this book is at its best when considering small and apparently discrete topics – its strength comes from being able to read all of these ideas on one place. … Overall, this book gives a thorough and detailed overview of the current state of basic and translational research into cancer immunology … . It’s probably most appropriate for researchers … .” (Victoria Lawson, Immunology News, November, 2011)

Textul de pe ultima copertă

The recent FDA approval of Provenge® as the first therapeutic cancer vaccine together with the recent demonstration that Ipilimumab®, a monoclonal antibody that blocks the negative immune checkpoint cytotoxic T lymphocyte associated antigen-4, prolongs patient survival are major achievements that usher in a new era of cancer immunotherapy. These “first-in-class” treatments reflect the substantive progress that basic and translational scientists have made towards understanding the mechanisms underlying protective tumor immunity in cancer patients Immunotherapies were first explored at the turn of the twentieth century, but the crafting of potent treatments required more detailed knowledge of how the immune system responds to cancer. Advances in genetic, cellular, and biochemical technologies have begun to yield this critical information, focusing attention on immune recognition, regulation, and escape. Indeed, the dynamic interplay of these processes in the tumor microenvironment is now recognized to play a decisive role in determining disease outcome. This volume highlights the rapid progress and breadth of research in cancer immunology, and provides a framework for anticipating many more clinical successes in cancer immunotherapy.

Caracteristici

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Includes supplementary material: sn.pub/extras

Cuprins

Immune infiltration in human cancer: prognostic significance and disease control.- Subversion and coercion - The art of redirecting tumor immune surveillance.- STAT3: A target to enhance antitumor immune response.- Biology and clinical observations of regulatory T cells in cancer immunology.- Dendritic cell subsets as vectors and targets for improved cancer therapy.- Identification of human idiotype-specific T cells in lymphoma and myeloma.- Modulation of CTLA-4 and GITR for cancer immunotherapy.- Immunologically active biomaterials for cancer therapy.- Subject index

Descriere

Descriere de la o altă ediție sau format:

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation of effector cells. To improve the clinical efficacy of cancer vaccines in patients with metastatic disease, we need to design novel and improved strategies that can boost adaptive immunity to cancer, help overcome Tregs and allow the breakdown of the immunosuppressive tumor microenvironment.